Lung Cancer Update
Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology/oncology fellows ongoing access to the perspectives and opinions of national and international research leaders with an expertise in thoracic oncology.
Episodes
Dr Anne Chiang, Dr Erin Schenk, and nurse practitioners Ms Elizabeth Krueger and Ms Beth Sandy discuss the role of bispecific antibodies in the management of small cell lung cancer and strategies to mitigate and manage treatment-emergent adverse events.
NCPD information and select publications here.
Prof Nicolas Girard, Dr Jonathan Goldman, Dr Pasi Jänne, Dr Suresh Ramalingam, Dr Joshua Sabari and moderator Dr Helena Yu present data informing treatment decision-making for EGFR-mutated NSCLC at the 2025 ASCO annual meeting.
CME information and select publications here.
Dr Jessica J Lin from Massachusetts General Hospital in Boston and Dr Joel W Neal from Stanford Cancer Institute in California summarize major treatment advances over the past year and review relevant ongoing clinical trials using targeted therapies for patients with non-small cell lung cancer.
CME information and select publications here.
Clinical investigators discuss available data guiding the management of non-small cell lung cancer with immunotherapy and other nontargeted approaches.
CME information and select publications here.
Clinical investigators discuss available data guiding the management of EGFR mutation-positive non-small cell lung cancer.
CME information and select publications here.
Dr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conjugates in the care of patients with breast and lung cancer and strategies to mitigate and manage treatment-emergent adverse events.
NCPD information and select publications here.
Dr Justin F Gainor from Massachusetts General Hospital in Boston reviews available clinical data on ALK inhibitors and first-line treatment strategies for ALK-positive metastatic non-small cell lung cancer.
CME information and select publications here.
EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances
Dr Enriqueta Felip from the Vall d’Hebron Institute of Oncology in Barcelona, Spain, and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, discuss current and emerging treatment approaches for patients with EGFR-mutant non-small cell lung cancer.
CME information and select publications here
Dr Edward B Garon shares his perspectives on the evolving therapeutic landscape for patients with lung cancer.
Dr Heather Wakelee from Stanford University School of Medicine in California discusses the implications of recent datasets for the current and future use of nontargeted therapy for metastatic non-small cell lung cancer.
Dr Suresh S Ramalingam from the Emory University School of Medicine in Atlanta, Georgia and Dr Gregory J Riely from Memorial Sloan Kettering Cancer Center in New York, New York discuss the implications of recent data sets for the current and future management of lung cancer.
Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with lung cancer.
Dr Stephen V Liu from Georgetown University Hospital in Washington, DC, reviews recently presented data with and newly approved therapies for localized and advanced lung cancers.
Dr Jacob Sands from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent presentations on approved and investigational therapies in small cell lung cancer from the 2024 World Conference on Lung Cancer.
Dr Edward Garon from UCLA Health Jonsson Comprehensive Cancer Center and Dr Luis Paz-Ares from the Spanish National Oncology Research Center in Madrid share their perspectives on recent datasets from the 2024 World Conference on Lung Cancer on the management of non-small cell lung cancer without actionable genomic alterations.
Dr Ibiayi Dagogo-Jack from Massachusetts General Hospital in Boston and Dr Corey J Langer from the Abramson Cancer Center in Philadelphia, Pennsylvania, discuss the implications of recent datasets for the current and future management of non-small cell lung cancer with actionable targets beyond EGFR.
Dr Joshua K Sabari from the NYU Langone Health Perlmutter Cancer Center and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for non-small cell lung cancer with EGFR mutations.
Dr Pamela Kunz from the Yale School of Medicine and Yale Cancer Center in New Haven, Connecticut, and Dr Simron Singh from the Odette Cancer Centre and Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada, discuss optimizing the diagnosis and treatment of neuroendocrine tumors.
Dr Pasi Jänne from the Dana-Farber Cancer Institute in Boston, Massachusetts, Prof Tom John from the Peter MacCallum Cancer Centre in Melbourne, Australia, Dr Zofia Piotrowska from Massachusetts General Hospital in Boston, Massachusetts, and Dr Alexander Spira from the Virginia Cancer Specialists Research Program in Fairfax, discuss recent updates on available and emerging treatment strategies for non-small cell lung cancer with an...
Prof Solange Peters from the Lausanne University Hospital in Lausanne, Switzerland, and Professor Ben Solomon from the Peter MacCallum Cancer Centre in Melbourne, Australia, discuss treatment approaches for ALK-rearranged non-small cell lung cancer in the localized disease setting.
Popular Podcasts
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
The latest news in 4 minutes updated every hour, every day.
Does hearing about a true crime case always leave you scouring the internet for the truth behind the story? Dive into your next mystery with Crime Junkie. Every Monday, join your host Ashley Flowers as she unravels all the details of infamous and underreported true crime cases with her best friend Brit Prawat. From cold cases to missing persons and heroes in our community who seek justice, Crime Junkie is your destination for theories and stories you won’t hear anywhere else. Whether you're a seasoned true crime enthusiast or new to the genre, you'll find yourself on the edge of your seat awaiting a new episode every Monday. If you can never get enough true crime... Congratulations, you’ve found your people. Follow to join a community of Crime Junkies! Crime Junkie is presented by audiochuck Media Company.
The Clay Travis and Buck Sexton Show. Clay Travis and Buck Sexton tackle the biggest stories in news, politics and current events with intelligence and humor. From the border crisis, to the madness of cancel culture and far-left missteps, Clay and Buck guide listeners through the latest headlines and hot topics with fun and entertaining conversations and opinions.
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com